Impaired insulin metabolism, hypertension, weight gain, and changes in serum lipids in patients receiving MMTPs may lead to long-term side effects, metabolic abnormalities, infections, chronic obstructive pulmonary disease, type 2 diabetes, and higher mortality [62–64]. Here, INS is linked to chronic obstructive pulmonary disease.